JP2023521076A5 - - Google Patents

Info

Publication number
JP2023521076A5
JP2023521076A5 JP2022560928A JP2022560928A JP2023521076A5 JP 2023521076 A5 JP2023521076 A5 JP 2023521076A5 JP 2022560928 A JP2022560928 A JP 2022560928A JP 2022560928 A JP2022560928 A JP 2022560928A JP 2023521076 A5 JP2023521076 A5 JP 2023521076A5
Authority
JP
Japan
Prior art keywords
modified virus
gene
e3gp19k
e1acr2
e1b19k
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022560928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521076A (ja
JP7758355B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/052898 external-priority patent/WO2021205364A1/en
Publication of JP2023521076A publication Critical patent/JP2023521076A/ja
Publication of JP2023521076A5 publication Critical patent/JP2023521076A5/ja
Application granted granted Critical
Publication of JP7758355B2 publication Critical patent/JP7758355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022560928A 2020-04-07 2021-04-07 設計された腫瘍溶解性アデノウイルス Active JP7758355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006115P 2020-04-07 2020-04-07
US63/006,115 2020-04-07
PCT/IB2021/052898 WO2021205364A1 (en) 2020-04-07 2021-04-07 Engineered oncolytic adenovirus

Publications (3)

Publication Number Publication Date
JP2023521076A JP2023521076A (ja) 2023-05-23
JP2023521076A5 true JP2023521076A5 (https=) 2024-04-16
JP7758355B2 JP7758355B2 (ja) 2025-10-22

Family

ID=78022983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560928A Active JP7758355B2 (ja) 2020-04-07 2021-04-07 設計された腫瘍溶解性アデノウイルス

Country Status (5)

Country Link
US (1) US20230149485A1 (https=)
EP (1) EP4133061A4 (https=)
JP (1) JP7758355B2 (https=)
CN (1) CN115605586B (https=)
WO (1) WO2021205364A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
DK2986311T3 (en) * 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
JP2021527694A (ja) * 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用

Similar Documents

Publication Publication Date Title
CN111658670B (zh) 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途
JPH06508039A (ja) 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
CN108165536A (zh) 一种重组溶瘤痘苗病毒及其制备方法与应用
JPH11500430A (ja) 外来遺伝子の生体内トランスフェクション及び発現に有用な併用医薬
JP2023521076A5 (https=)
CN112840020A (zh) 溶瘤病毒及其应用
US12421502B2 (en) Enhanced adoptive cell therapy
JP7758355B2 (ja) 設計された腫瘍溶解性アデノウイルス
Blum Molecular therapy and prevention of liver diseases.
Hua et al. Progression of oncolytic virus in liver cancer treatment
Zhao et al. Progression of oncolytic virus
CN113573741B (zh) 修饰腺病毒和含有其的医药
CN118773145A (zh) 一种表达i型干扰素和pkr干扰rna的重组hsv-1溶瘤病毒及其构建方法和应用
JP2016160249A (ja) 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤
HK40028530B (zh) 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途
CN115779092A (zh) Serpine1抑制剂在制备用于促进抗肿瘤免疫治疗功效的药物中的应用
CN113544263A (zh) 溶瘤病毒载体及其应用
CN117883577A (zh) Birc2抑制剂在制备用于增强肿瘤细胞对免疫杀伤的敏感性的药物中的应用
HK40056333A (en) Modified adenovirus and medicine comprising same
HK40054249B (zh) 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
Aa BDCA3+ Dendritic Cells and Their Function in Chronic Hepatitis B Virus Infection